New HIV Vaccine With a 97% Antibody Response Rate Shows Promise in ‘Landmark’ First-in-Human Trial

A novel vaccine approach for the prevention of HIV has shown promise in Phase I trials. IAVI and Scripps Research reported that the vaccine which is being developed to act as an immune primer, to trigger the activation of naïve

Read More New HIV Vaccine With a 97% Antibody Response Rate Shows Promise in ‘Landmark’ First-in-Human Trial